Rob de Ree
Rob de Ree is CEO of NorthSea Therapeutics and he is a venture partner at BGV. Rob is serving on the board of Mellon Medical, previously he was the Chairman of SurgVision and Ventinova medical.
Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various national and international sales and marketing roles. Rob moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences. Rob was subsequently CEO of Dezima Pharma, which was sold to Amgen in October 2015.
Rob holds a MSc in pharmacy from the University of Groningen.